PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION

Abstract

Anemia is an integral component of CKD. The prescribing of erythropoiesis stimulating agents (ESA) for the treatment of anemia constitutes a significant burden on health budgets. Using of continuous erythropoietin receptor activator (CERA) and convective techniques can improve health indicators and economic results. The aim of the study was to evaluate the effects of hemodiafiltration treatment (HDF) on the pharmaco-economic efficiency of anemia treatment in comparison with haemodialysis (HD). Methods. A prospective cross-sectional study involving 40 patients with CKD stage V who receiving dialysis treatment at the LLC “Fresenius Medical Care Ukraine ” Medical center in Cherkasy city. The follow-up period was 2 years. First, data was analyzed while patients received HD over a period of twelve months. Then, the same patients were evaluated during treatment with HDF for at least another twelve months. Result. The average dose of CERA reduced from 60 mg to 44 mg per month (p = 0.002) after the transferred ofpatients to HDF treatment. There were a significantly increased the levels of Kt / V (p = 0.04) and serum albumin (p = 0.04). A higher number of patients achieved the target hemoglobin results. Conclusions. The comparison of pharmaco-economic component of anemia correction with CERA cross-sectional study demonstrates significant advantages of HDF treatment compared to HD.

Authors and Affiliations

V. Novakivskyy

Keywords

Related Articles

BACTERIAL SUSCEPTIBILITY-RESISTANCE LEVELS OF CHRONIC PYELONEPHRITIS PATHOGENS’, DEPENDING ON EXPRESSION OF DIFFERENT TYPES OF PLASMID-MEDIATED RESISTANCE GENES

The aim of the study is to determine the bacterial susceptibility-resistance levels of uropathogens depending on expression of different types of plasmid-mediated resistance genes. Methods. A cross-sectional study of105...

ОСОБЛИВОСТІ КЛІНІЧНОЇ ТА ЛАБОРАТОРНОЇ ДІАГНОСТИКИ ХВОРОБИ ФАБРІ

Мета роботи – визначення клінічних особливостей та молекулярно–генетичних характеристик пацієнтів з хворобою Фабрі (ХФ) для оптимізації послідовності діагностичних заходів. Об’єкт і методи. У120 осіб чоловічої статі з а...

Age-related oxidative stress in patients with pyelonephritis

The objective of the present study was to compare age-related oxidative stress in pediatric and adult patients with pyelonephritis. Methods. This research is focused on the age features of change of oxidant-antioxidant...

Використання подвійного J-стенту у реципієнтів ниркового трансплантату: звіт про когорту одного центру

Трансплантація нирок є методом вибору для лікування термінальної стадії хронічної хвороби нирок. Подвійний J стент зазвичай використовується під час трансплантації нирок. Частота урологічних ускладнень коливається в межа...

Treatment of urinary tract infections in condition of growing antibiotic resistance: Antimicrobial Stewardship program

Resistance to common groups of antibiotics has been increasing in the treatment of urinary tract infections worldwide. In the United States, CDC has estimated that more thаn 2 million infections and 23,000 deaths are due...

Download PDF file
  • EP ID EP353731
  • DOI 10.31450/ukrjnd.1(53).2017.04
  • Views 74
  • Downloads 0

How To Cite

V. Novakivskyy (2017). PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION. УКРАЇНСЬКИЙ ЖУРНАЛ НЕФРОЛОГІЇ ТА ДІАЛІЗУ, 1(53), 26-31. https://europub.co.uk/articles/-A-353731